Neximmune, INC 8-K filings

NexImmune's board and executive team resign en masse as the company moves forward with its plan of liquidation and dissolution.

NexImmune stockholders voted to approve the company's dissolution and liquidation plan at a special meeting held on August 9, 2024.

NexImmune has adjourned its special meeting to vote on liquidation, seeking alternatives to maximize value, and will reconvene on August 9, 2024.

NexImmune has adjourned its special meeting of stockholders to explore alternatives to liquidation, with the meeting scheduled to reconvene on August 2, 2024.

NexImmune, Inc. has received a delisting notice from Nasdaq and has adjourned a special meeting to consider liquidation, while it explores alternatives to maximize value.

NexImmune, Inc. has amended its bylaws to change quorum requirements and created a Series A Preferred Stock with special voting rights related to potential liquidation.

NexImmune, Inc. has announced the resignation of its principal financial officer, Timothy Stover, and the appointment of Albert N. Marchio II as interim CFO, effective April 16, 2024.

NexImmune has entered into a definitive agreement for a $3.67 million registered direct offering, leading to the postponement of a special meeting to vote on liquidation.

NexImmune, Inc. has terminated its $50 million at-the-market offering program, effective immediately, after raising $5.1 million through the sale of 127,396 shares.

NexImmune is facing potential delisting from Nasdaq and is seeking additional financing to avoid liquidation, with existing funds expected to last only until mid-February 2024.

NexImmune's special meeting to vote on liquidation was adjourned due to insufficient shareholder representation, with a reconvened meeting scheduled for February 7, 2024.